<DOC>
	<DOCNO>NCT02433678</DOCNO>
	<brief_summary>This single center , prospective , randomize , placebo -controlled , parallel design double blind study evaluate oxidative stress , inflammation hypertension marker mediator treatment dapagliflozin .</brief_summary>
	<brief_title>An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin</brief_title>
	<detailed_description>Two group 26 patient ( total 52 patient ) type 2 diabetes oral agent include study . One group randomize dapagliflozin ( dose 5 mg daily titrate 10 mg daily first week ) placebo . The patient treat 12 week . Only half patient ( equal number group ) test secondary endpoint relate postprandial single dose induce change . The primary endpoint study detect significant difference percent change fast Nuclear factor-k B ( NFκB ) activation ( DNA bind activity ) mononuclear cell ( MNC ) dapagliflozin use ( 0 week vs. 12 week ) compare placebo .</detailed_description>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Age 2080 year inclusive . Type 2 diabetes BMI ≥30 kg/m2 Subjects statin , ACE inhibitor , ARBs , thiazolidinediones antioxidant allow long stable dos compound dosage change course study . Patients evenly distribute 2 group base statin , ARBs , TZDs ACE inhibitor use . HbA1c ≤ 8.0 % Use GLP1 agonists DPPIV SGLT2 inhibitor therapy last 3 month . Risk pancreatitis , i.e. , history gallstone , alcohol abuse , hypertriglyceridemia . Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous 3 month . Hepatic disease : Severe hepatic insufficiency and/or significant abnormal liver function define : aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN Total bilirubin &gt; 2.0 mg/dL ( 34.2 µmol/L ) Positive serologic evidence current infectious liver disease include Hepatitis B viral antibody IGM , Hepatitis B surface antigen Hepatitis C virus antibody ( liver function test 3 time upper limit normal ) Renal impairment ( serum eGFR &lt; 60 ml/min ) Any lifethreatening , noncardiac disease Uncontrolled hypertension ( BP &gt; 160/100 mm Hg ) Congestive Heart Failure class III IV . Use investigational agent therapeutic regimen within 30 day study Participation concurrent clinical trial pregnant breastfeeding patient Volume deplete patient . Patients risk volume depletion due coexist condition concomitant medication , loop diuretic</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>